UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants (IRB 2004-535)

National Cancer Institute (NCI)

Status and phase: Completed; Phase 1

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Treatments: Drug: resveratrol

Study type: Interventional

Funder types: NIH

Identifiers

NCT00098969

CDR0000396464

P30CA046592 (U.S. NIH Grant/Contract)

CCUM-2062

CCUM-2004-0535

Details and patient eligibility

About

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of resveratrol may prevent cancer.

PURPOSE: This phase I trial is studying the side effects and best dose of resveratrol in preventing cancer in healthy participants.

Full description

OBJECTIVES:

• Determine the concentration of resveratrol and its metabolites in the plasma, urine, and feces of healthy participants.
• Correlate dose with systemic concentration of this drug and its metabolites in these participants.
• Determine the safety of this drug in these participants.

OUTLINE: This is an open-label, dose-escalation, multicenter study.

Beginning 5 days before study drug administration, participants are put on a controlled diet (avoiding all resveratrol-containing food or drink) for washout. Participants receive oral resveratrol once on day 1.

Cohorts of 10 participants receive escalating doses of resveratrol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 10 participants experience dose-limiting toxicity. A total of 16 participants are treated at the MTD.

Participants are followed at 2 and 7 days.

PROJECTED ACCRUAL: A total of 10-40 participants will be accrued for this study within 6 months.

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Healthy participants

PATIENT CHARACTERISTICS:

Age

• 18 to 80

Performance status

• WHO 0-1

Life expectancy

• Not specified

Hematopoietic

• Absolute neutrophil count > 1,500/mm^3
• Platelet count 120,000-450,000mm^3
• Hemoglobin 10.5-17.5 g/dL for women OR 11.5-19.0 g/dL for men

Hepatic

• Bilirubin 0.05-1.2 mg/dL
• AST and ALT < 1.5 times normal

Renal

• Creatinine normal
• Urinalysis normal

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile participants must use effective contraception
• Willing to abstain from ingesting large quantities of resveratrol-containing foods
• Willing to spend 24 hours in the hospital
• No cancer diagnosis that is currently under treatment, is clinically detectable, or that has been treated within the past 5 years except basal cell or squamous cell skin cancer
• No concurrent excessive alcohol intake (>21 units per week for men; 14 units per week for women)

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• Not specified

Endocrine therapy

• Concurrent hormone replace ment therapy allowed
• Concurrent oral or depot contraceptives allowed

Radiotherapy

• Not specified

Surgery

• Not specified

Other

• At least 2 weeks since prior and no concurrent vitamin supplements of any type
• More than 6 months since prior and no concurrent participation in any other experimental study
• No other concurrent chronic medications, including over-the-counter medications, herbal/natural preparations, or dietary supplements
• No other concurrent prescribed medication